Prevalence of Obesity With and Without Confirmation of Excess Adiposity Among US Adults

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity - PressReach

– The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants with obesity. – As an adipose-targeted, muscle-preserving weight loss drug candidate for the treatment of obesity, ASC47 monotherapy demonstrated a half-life of up to 40 days in a Phase Ib study in participant…

– This combination study aims to evaluate the safety and preliminary efficacy of a single dose of ultra-long-acting subcutaneous ASC47 combined with four doses of semaglutide (0.5 mg, once weekly) in obese subjects. – As a fat-targeted drug candidate for the treatment of obesity that reduces weight without losing muscle, ASC47 monotherapy showed a half-life of up to 40 days in a Phase Ib study in obese subjects. – In a head-to-head comparison of…

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants with obesity.

Prevalence of Obesity With and Without Confirmation of Excess Adiposity Among US Adults

This study compares the prevalence of obesity (assessed by body mass index only) vs obesity prevalence when excess adiposity is confirmed by waist circumference measurement or dual-energy x-ray absorptiometry in a nationally representative sample of US adults.